197 related articles for article (PubMed ID: 15374888)
1. Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease.
Blaser BW; Roychowdhury S; Kim DJ; Schwind NR; Bhatt D; Yuan W; Kusewitt DF; Ferketich AK; Caligiuri MA; Guimond M
Blood; 2005 Jan; 105(2):894-901. PubMed ID: 15374888
[TBL] [Abstract][Full Text] [Related]
2. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.
Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation.
Min CK; Maeda Y; Lowler K; Liu C; Clouthier S; Lofthus D; Weisiger E; Ferrara JL; Reddy P
Blood; 2004 Nov; 104(10):3393-9. PubMed ID: 15280194
[TBL] [Abstract][Full Text] [Related]
4. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
5. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.
Yang YG; Dey BR; Sergio JJ; Pearson DA; Sykes M
J Clin Invest; 1998 Dec; 102(12):2126-35. PubMed ID: 9854048
[TBL] [Abstract][Full Text] [Related]
6. Host conditioning is a primary determinant in modulating the effect of IL-7 on murine graft-versus-host disease.
Gendelman M; Hecht T; Logan B; Vodanovic-Jankovic S; Komorowski R; Drobyski WR
J Immunol; 2004 Mar; 172(5):3328-36. PubMed ID: 14978141
[TBL] [Abstract][Full Text] [Related]
7. Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells.
Foley JE; Mariotti J; Ryan K; Eckhaus M; Fowler DH
Biol Blood Marrow Transplant; 2008 Sep; 14(9):959-972. PubMed ID: 18721759
[TBL] [Abstract][Full Text] [Related]
8. APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease.
Zhang Y; Shlomchik WD; Joe G; Louboutin JP; Zhu J; Rivera A; Giannola D; Emerson SG
J Immunol; 2002 Dec; 169(12):7111-8. PubMed ID: 12471148
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin attenuates acute gastrointestinal graft-versus-host disease by preventing apoptosis of intestinal epithelial cells.
Kawakami K; Minami N; Matsuura M; Iida T; Toyonaga T; Nagaishi K; Arimura Y; Fujimiya M; Uede T; Nakase H
Biochem Biophys Res Commun; 2017 Apr; 485(2):468-475. PubMed ID: 28192120
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation.
Alpdogan O; Eng JM; Muriglan SJ; Willis LM; Hubbard VM; Tjoe KH; Terwey TH; Kochman A; van den Brink MR
Blood; 2005 Jan; 105(2):865-73. PubMed ID: 15280205
[TBL] [Abstract][Full Text] [Related]
11. The identification and characteristics of IL-22-producing T cells in acute graft-versus-host disease following allogeneic bone marrow transplantation.
Zhao K; Zhao D; Huang D; Song X; Chen C; Pan B; Wu Q; Cao J; Yao Y; Zeng L; Xu K
Immunobiology; 2013 Dec; 218(12):1505-13. PubMed ID: 23816304
[TBL] [Abstract][Full Text] [Related]
12. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
13. Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity.
Blaser BW; Schwind NR; Karol S; Chang D; Shin S; Roychowdhury S; Becknell B; Ferketich AK; Kusewitt DF; Blazar BR; Caligiuri MA
Blood; 2006 Oct; 108(7):2463-9. PubMed ID: 16757683
[TBL] [Abstract][Full Text] [Related]
14. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients.
Marks L; Altman NH; Podack ER; Levy RB
Transplantation; 2004 Mar; 77(6):804-12. PubMed ID: 15077018
[TBL] [Abstract][Full Text] [Related]
15. IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation.
Sun K; Hsiao HH; Li M; Ames E; Bouchlaka M; Welniak LA; Hagino T; Jagdeo J; Pai CC; Chen M; Blazar BR; Abedi M; Murphy WJ
J Immunol; 2012 Aug; 189(4):2033-42. PubMed ID: 22778394
[TBL] [Abstract][Full Text] [Related]
16. Relationship between CCR5 and acute graft-versus-host disease in murine bone marrow transplantation.
Wang Z; Murphy WJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct; 14(5):934-40. PubMed ID: 17096892
[TBL] [Abstract][Full Text] [Related]
17. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease.
Pan L; Delmonte J; Jalonen CK; Ferrara JL
Blood; 1995 Dec; 86(12):4422-9. PubMed ID: 8541530
[TBL] [Abstract][Full Text] [Related]
19. The fate of donor T-cell receptor transgenic T cells with known host antigen specificity in a graft-versus-host disease model.
Dey B; Yang YG; Preffer F; Shimizu A; Swenson K; Dombkowski D; Sykes M
Transplantation; 1999 Jul; 68(1):141-9. PubMed ID: 10428282
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
